Bayer Raises Full-Year Guidance After Third-Quarter Earnings Beat
Bayer raised its full-year guidance. Jefferies analysts said the increase appears to reflect how much third-quarter earnings exceeded expectations; strong pharmaceutical performance drove group adjusted EBITDA above expectations.
Bayer raised its full-year guidance, but the increase seems to reflect the margin by which its third-quarter earnings beat expectations, analysts at Jefferies write in a note to clients. A strong performance in the German company's pharmaceutical division drove group-level adjusted Ebitda to exceed…